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Editorial
In primary care settings, approximately 30% to 50% of patients have prominent psy-
chiatric symptoms or identifiable mental disorders, which are of significant adverse 
consequences if left untreated.1 Even in surgical specialties, many presurgical and 
postsurgical developments are associated with significant mental health issues. 
Recent trends in medicine promote the further integration of psychiatry into the main-
stream of medical practice, and emphasize the importance of attending to patients 
with psychiatric symptoms regardless of the clinician’s medical specialty.2 We hope 
this issue of the Journal will remind our readers of this important aspect of patient 
care.
References:
1. Weissman MM, Neria Y, Gameroff JJ, et al. Positive screens for psychiatric disorders in primary care: A long-term follow-up of patients who were not in 
treatment. Psychiatr Serv 2010;61:151-159.
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Dr lam Tat Chung, Paul
林達聰醫生
FRCP, FHKAM (Medicine),  
FHKAM (Psychiatry)
President
Dr lau Chu Pak 
劉柱柏醫生
FRCP, MD, FHKAM (Medicine) 
Chief Editor
54 Journal of The Society of Physicians of Hong Kong
Major	Depressive	Disorder	–	
Treatment	Options	Other	Than	SSRI
Depression is a complex syndrome that includes many different symptoms. With depressive mood as a core symptom, the 
condition is also associated with tiredness, 
loss of drive and motivation, poor con-
centration and cognitive functioning, 
impairment of attention or alertness, an-
hedonia and sexual dysfunction, agitation 
and irritability, aggression, anxiety, hyper-
somnia or insomnia, feeling of guilt, sui-
cidality, dyscontrol of appetite and weight, 
and many associated physical symptoms. 
The pharmacological treatment 
of depression evolves around the un-
derstanding and manipulation of the 
monoamine systems, namely the sero-
tonergic, noradrenergic and dopaminergic 
systems. The interplay between these 
systems is not fully understood, but the 
adequacy and proper functioning of each 
of the monoamines has been shown to 
be important for the maintenance of a 
normal mood. Drugs have been developed 
to target each of the three systems to al-
leviate the disorder.
Currently, the most widely pre-
scribed group of drugs for the treatment 
of depression is the selective serotonin 
reuptake inhibitors (SSRIs). This group 
of drugs is deemed as a great advance 
over the older antidepressants such as 
monoamine oxidase inhibitors (MAOIs) 
and tricyclics in terms of side effect profile 
and safety. Though a welcomed addition 
to the armamentarium, there remains 
many problems and inadequacies that 
need to be addressed or improved. These 
include the lack of efficacy in some pa-
tients, sexual dysfunction, weight gain, 
sedation, withdrawal symptoms, etc.
In the Sequenced Treatment Alter-
native to Relieve Depression (STAR*D) 
trial, an important large-scale study com-
missioned by the US National Institute of 
Mental Health, treatment with the SSRI 
citalopram for about 10 weeks resulted in 
a remission rate of only around 30%.1  
An amotivational syndrome has 
been described in patients following use 
of SSRIs for several months. In these 
patients, although the depression im-
proved, a state of apathy and indifference 
developed, which could be temporarily al-
leviated by a dose reduction of the SSRI. 
The addition of a noradrenergic agent im-
proved the condition.2,3 Other problems 
included bleeding tendencies and the 
syndrome of inappropriate antidiuretic 
hormone secretion.
Alternative medications have been 
developed to address the shortcomings 
of the SSRIs, and for the group of patients 
who require treatment for certain specific 
symptoms in the depressive syndrome 
by tackling different monoaminergic 
systems. (Table) While some medications 
modulate the noradrenergic system, bu-
propion is the only medication currently 
available that can effectively target the 
dopaminergic system as well. Different 
symptom groups that are controlled by 
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Table.	Neurotransmitter	effects	of	antidepressants
Norepinephrine/noradrenaline	(NE)	 Serotonin	(5-HT) Dopamine	(DA)
SSRIs √
Bupropion SR √ √
Mirtazapine √ √
Nefazodone √ √
Venlafaxine √ √
SR = sustained release; SSRI = selective serotonin reuptake inhibitor
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the three different monoamines are illus-
trated in Figure 1.4
Bupropion is a monocyclic ami-
noketone that has been used for 
the treatment of major depression 
since 1989. It belongs to the class of 
norepinephrine-dopamine reuptake in-
hibitors (NDRIs). Sustained-release (SR) 
tablets (150 mg) were available in the US 
since 1996, and extended-release (XR) 
tablets (300 mg) since 2003.
Efficacy Studies
A pooled analysis of six randomized con-
trolled trials showed that remission rate 
with bupropion was similar to SSRIs 
and better than placebo.5 (Figure 2) 
Other studies have shown comparable 
remission rates with escitalopram and 
venlafaxine.6-9 (Figure 3) Bupropion has 
also been shown to confer superior 
benefit in patients complaining of reduced 
energy, pleasure and interest.10
Treatment Switching 
In the STAR*D trial, switching to bu-
propion SR, sertraline or venlafaxine 
resulted in similar remission rates of 
26% to 28% in patients previously non- 
responsive to citalopram.11
Combination Therapy
In the above trial, the addition of bu-
propion SR resulted in a remission rate 
of 39% in patients previously not re-
sponding to citalopram alone. This is 
much better than the remission rate of 
32.9% with buspirone augmentation. 
Other more favourable outcomes with 
the bupropion combination include 
treatment adherence, adverse reaction 
and change in the Quick Inventory of De-
pressive Symptomatology – Self Report 
(QIDS-SR) score.12
other Benefits
Sexual dysfunction occurs in 20% to 60 % 
of patients treated with SSRIs. This may 
pose significant distress to depressed 
patients and compromise their quality 
of life. Bupropion is not associated with 
sexual dysfunction including orgasmic 
dysfunction, sexual arousal disorder and 
sexual desire disorder.13 
Most antidepressants including 
SSRIs, mirtazapine, tricyclics and MAOIs 
cause weight gain. No such adverse 
effect is observed with bupropion. The 
agent may induce more weight loss than 
placebo in obese adults.14 
Anxiety frequently occurs in de-
pressed patients. Bupropion SR compares 
favourably with SSRI in the control of 
anxiety symptoms.15
Figure	1.	Different	symptom	groups	controlled	by	serotonin,	noradrenaline	and	dopamine
Adapted from reference 4. 
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Figure	2.	Remission	rates	with	bupropion	and	SSRIs:	Pooled	
analysis	of	6	RcTs
* Escitalopram (2), paroxetine (1), sertraline (3)
** p<0.0001 vs placebo
HAM-D = Hamilton Depression Rating Scale; RCT = randomized 
controlled trial; SSRI = selective serotonin reuptake inhibitor Adapted from reference 5.
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Figure	3.	Remission	rates	with	bupropion	xR	vs	escitalopram
“Remission rate with 
bupropion was similar 
to SSRIs”
Neurotransmitters	regulate	mood,	cognition	and	behaviour
NORADRENALINE Serotonin
DOPAMINE
Vigilance
Energy
Impulse
Anxiety
Irritability
Mood
Emotion
cognitive	
function
Motivation
Appetite
Sex
Aggression
attention
Motivation
Pleasure
HAMD-17 = 17-item Hamilton Depression Rating Scale;  
XR = extended release  Adapted from reference 6.
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Adverse Effects
The more frequent adverse effects are 
headache, insomnia, nausea, vomiting, 
dry mouth, and sweating. 
Special Patient Groups
Bupropion has to be used with care in 
patients with hepatic failure or renal im-
pairment. Caution should be exercised 
in patients prone to or with a history of 
seizure. The agent is classified under 
FDA Pregnancy Category B, while SSRIs 
are classified less favourably under 
Category C. 
Conclusion
Bupropion SR (150 mg) given as a single 
morning dose is an appropriate and 
efficacious choice for the treatment of 
patients with major depressive disorder, 
or for combination therapy with SSRIs. Its 
unique mechanism of noradrenergic and 
dopaminergic reuptake inhibition makes it 
an effective antidepressant, with special 
benefit for symptoms such as loss of 
energy and motivation, tiredness, hy-
persomnia and anhedonia. It has special 
favourable profiles with regard to sexual 
function, body weight, control of anxiety 
symptoms and lack of sedation. In some 
patients, the dose can be increased to 
150 mg twice daily if required.  
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Long-term	Treatment	of	Relapsing-
Remitting	Multiple	Sclerosis
patients have oligoclonal bands (OCB) 
in cerebrospinal fluid (CSF).1,2 Asians 
have a lower prevalence of CMS than 
Caucasians; it has been reported that 
relatively higher proportions of Asian MS 
patients have opticospinal MS (OSMS), in 
which there is predominant involvement 
of optic nerves and spinal cord, and a 
lower frequency of CSF OCB.3,4 Recent 
evidence strongly suggests that OSMS is 
in fact neuromyelitis optica (NMO), also 
called Devic’s disease, which is distinct 
from CMS.5,6 RRMS patients develop 
recurrent attacks of inflammatory de-
myelination affecting the cerebral hemi-
spheres, brainstem, cerebellum, spinal 
cord (myelitis) and optic nerves (optic 
neuritis), which are associated with good 
neurological recovery especially in early 
attacks; in contrast, relapsing NMO pa-
tients typically develop recurrent severe 
attacks of myelitis and optic neuritis as-
sociated with early irreversible neuro-
logical disabilities.6-8 Importantly, CMS 
patients are seronegative for NMO- 
immunoglobulin G (IgG), an autoantibody 
targeting the aquaporin-4 water channel 
and a specific biomarker for NMO, while 
about 60% to 73% of NMO patients 
are seropositive for NMO-IgG.5 Hence, 
early serological testing for NMO-IgG is 
useful in prompt diagnosis of NMO and 
its distinction from CMS in patients who 
present with myelitis or optic neuritis.5 
Most RRMS patients have satis-
factory recovery from acute attacks in 
the early phase; unfortunately, an accu-
mulating number of patients will develop 
secondary progressive MS (SPMS) char-
acterized by irreversible progressive 
neurological deterioration and disability 
accumulation with or without acute 
relapses.1,2,9,10 Natural history studies 
estimate that RRMS patients develop 
SPMS at a rate of 2% to 3% per 
year,1,2,9-17 and the median time to reach 
the Expanded Disability Status Scale 
(EDSS) score of 6 (ie, need of unilateral 
assistance to walk for 100 metres) is es-
timated to be about 19 years.14 Axonal 
degeneration is believed to be the key 
pathology underlying SPMS.18 Impor-
tantly, axonal injury can occur and be 
severe early in RRMS.18-21 Hence, in the 
absence of effective treatments that can 
prevent or delay progression to SPMS, 
the majority of RRMS patients are at risk 
of significant neurological disability in the 
long term in view of the chronic nature 
and predominantly young onset age of 
this disorder.  
Aetiological Factors
The exact pathogenetic mechanisms of 
MS are uncertain.1,2,22 Genetic factors 
contribute to its aetiology as evidenced 
by the concordance rate of 31% among 
monozygotic twins vs 5% for dizygotic 
twins; moreover, the presence of the 
HLA-DR2 antigen increases an indi-
vidual’s susceptibility to CMS.2,23 Multiple 
genes influence the susceptibility to de-
veloping MS, but no single gene with the 
possible exception of HLA has a strong 
influence.1,2
Environmental factors also play a 
role, as evidenced by the change in MS 
frequency among individuals and their 
offspring who migrate into and out of 
high-prevalence areas.24 Infection by 
micro-organisms including herpes 
simplex virus type 6  and Chlamydia 
pneumoniae is suggested to be a 
causative factor,25,26 but confirmation 
from other studies is lacking. 
Diagnosis
The diagnosis of RRMS is suggested by 
a history of recurrent attacks of injury 
to different sites of the CNS, followed 
Key	words:	
Relapsing-remitting multiple 
sclerosis (復發緩解型多發性硬
化), beta-interferons (乙型干擾
素), natalizumab 
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Introduction
Multiple sclerosis (MS) is a chronic immune-mediated disorder characterized by in-flammatory demyelination of 
the central nervous system (CNS).1,2 Ap-
proximately 85% of patients with classical 
MS (CMS) have relapsing-remitting MS 
(RRMS) at onset, characterized by re-
current attacks of inflammatory demyeli-
nation and axonal injury affecting different 
sites of the CNS. About 90% of CMS 
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by partial or complete resolution of 
symptoms.  Physical findings of abnor-
malities at multiple CNS sites such as cer-
ebellar ataxia from cerebellar involvement 
and paraparesis with a sensory level from 
spinal cord involvement support the di-
agnosis. Magnetic resonance imaging 
(MRI) of multiple white matter lesions 
at different sites of the CNS (ie, spatial 
dissemination) and lesions with dif-
ferent ages (ie, temporal dissemination, 
shown by new lesions on repeated MRI) 
greatly facilitate the diagnosis, especially 
in patients who presented with the first 
clinical attack, known as clinically isolated 
syndrome (CIS), based on fulfillment of 
the revised McDonald criteria.27 Lumbar 
puncture for exclusion of CNS infection 
and detection of CSF OCB helps to 
support the diagnosis. Other disorders 
that mimic RRMS must be excluded, 
especially relapsing NMO (by testing for 
NMO-IgG) and vasculitis such as cerebral 
lupus (by testing for autoimmune markers 
including antinuclear antibody [ANA] and 
anti-extractable nuclear antigen [anti-ENA] 
antibody). 
Treatments
Aims and Approach
Treatment aims at: 1) reduction of relapse 
rate, 2) prevention of fixed disability di-
rectly attributable to relapse, 3) symp-
tomatic treatment of fixed neurological 
deficits, and 4) prevention or delay of 
development of SPMS, hence minimizing 
permanent disability. It is encouraged to 
adopt a multidisciplinary team approach, 
in which different professionals including 
neurologist, nurse specialist, physio-
therapist, occupational therapist, rehabili-
tation specialist and clinical psychologist 
contribute to patient care by providing 
expertise in management of a chronic 
neurological disorder. This review will 
address the long-term pharmacological 
treatment of RRMS.
long-term Disease-modifying 
Drugs 
Intravenous pulse methylprednisolone 
0.25–1 g daily for 3 to 5 days is indicated 
during acute attacks associated with po-
tentially significant disability to hasten 
neurological recovery; however, the 
benefit on long-term neurological dis-
ability is uncertain.1,2 Regular intermittent 
intravenous pulse corticosteroid and 
regular oral corticosteroid therapies are 
ineffective for reduction of relapse fre-
quency. Currently, four disease-modifying 
drugs (DMDs) are approved for use in 
RRMS. These are beta-interferon (β-IFN) 
(1a and 1b), glatiramer acetate (GA), na-
talizumab and mitoxantrone.2
Beta-interferon 
β-IFN 1a and 1b are first-line immuno-
modulatory therapies for RRMS. Their 
short-term efficacy (for 2 to 3 years) in 
reducing relapse frequency by about 
one-third is well proven.28-30 
β-IFN 1a and 1b possess anti-inflam-
matory properties, inhibit T cell activation 
and reduce blood-brain barrier perme-
ability to inflammatory cells.28 Therapy re-
quires subcutaneous injection 3 times a 
week or on alternate days. Common side 
effects are local injection site reactions, 
flu-like symptoms with fever (which tend 
to subside after several weeks in most 
patients who continue with therapy), and 
reversible liver function derangement as 
evidenced by raised parenchymal liver 
enzyme levels.28  In addition, 5% to 30% 
of treated patients develop persistent 
neutralizing antibodies that are asso-
ciated with reduced treatment effect on 
relapse frequency.2 Long-term benefits in 
prevention or reduction of disability are 
uncertain, and patients or carers need 
to perform subcutaneous injection. The 
ideal timing for starting β-IFN in RRMS is 
controversial.31,32 The author is in favour 
of early initiation of DMD once the di-
agnosis of RRMS is confirmed and when 
the disease is active, as evidenced by 
clinical relapse or MRI evidence of sub-
clinical active inflammation. 
Glatiramer Acetate 
GA is a synthetic co-polymer structurally 
similar to myelin basic protein (MBP). 
Therapy requires daily subcutaneous 
injection. GA is thought to induce T cell 
anergy, inhibition of MBP-reactive T lym-
phocytes and induction of T helper 2 lym-
phocytes, resulting in an anti-inflammatory 
action.33 GA reduces relapse frequency of 
RRMS by about 30%, and improves MRI 
parameters of disease activity. Its efficacy 
is similar to that of β-IFN. GA is generally 
safe and well tolerated. Similar to β-IFN, 
its benefit on long-term disability is 
uncertain.
Natalizumab
Lymphocyte migration across the 
blood-brain barrier is an important early 
step in the formation of lesions in MS.1,22 
α4 integrins are a family of adhesion mol-
ecules expressed on the surface of lym-
phocytes, functioning as an important 
mediator of cell adhesion and transen-
dothelial migration, and a regulator of 
immune cells activation within inflamed 
tissue.34,35 Natalizumab is a humanized 
monoclonal antibody against the α4 in-
tegrins, which selectively blocks the 
binding of α4β1 and α4β7 integrins to their 
endothelial receptors, hence inhibiting 
migration of lymphocytes into the brain 
and reducing inflammation.
A randomized double-blind trial of 
213 patients with RRMS or relapsing 
SPMS treated with intravenous natal-
izumab (3 mg/kg or 6 mg/kg) or placebo 
every 28 days for 6 months showed that 
active treatment was associated with 
reductions in relapse frequency and the 
number of new enhancing brain lesions 
over the 6-month period. However, such 
differences disappeared upon an addi-
tional 6 months’ follow-up.36
More recently, natalizumab was 
shown to be effective in RRMS by re-
ducing the relapse rate at 1 year by 68%, 
and the risk of sustained progression of 
disability by 42% over 2 years in a 2-year 
phase III clinical trial.37 The cumulative 
probability of progression was 17% in the 
natalizumab group vs 29% in the placebo 
group. Furthermore, the addition of na-
talizumab to β-IFN 1a reduced the risk of 
disability progression by 24% and annu-
alized relapse rate by 55% over a 2-year 
period, compared with β-IFN 1a alone.38 
Currently, natalizumab is recom-
mended for RRMS patients who failed to 
respond to β-IFN, or RRMS patients with 
very aggressive disease that may be sta-
bilized with natalizumab first followed by 
stepping down of therapy to β-IFN or GA. 
Some patients will develop neutralizing 
antibodies against natalizumab, which 
may cause hypersensitivity reactions and 
loss of drug efficacy over time. Patients 
reacting to or showing poor response to 
natalizumab may need testing for anti-
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bodies. Importantly, patients treated with 
natalizumab, especially when preceded 
by other immunosuppressant therapy or 
used in combination with β-IFN, rarely 
develop progressive multifocal leukoen-
cephalopathy (PML) due to latent JC virus 
infection. The risk of PML related to na-
talizumab therapy is estimated to be 1 in 
1,000 (0.1%) over an 18-month treatment 
period.39 It is generally accepted that the 
beneficial effects of natalizumab in active 
RRMS outweigh the risk of PML.40
Mitoxantrone 
Mitoxantrone is a synthetic anthra-
cenedione with cytotoxic and immu-
nosuppressive effects. It inhibits DNA 
repair and synthesis in dividing and non-
dividing cells by inhibiting DNA topoi-
somerase II, suppresses T and B cells, 
induces apoptosis in antigen-presenting 
cells, and deactivates macrophages.41,42 
A randomized double-blind trial of 194 
patients with worsening RRMS or SPMS 
treated with mitoxantrone (5 mg/m2 or 
12 mg/m2) or placebo 3-monthly for 2 
years showed that mitoxantrone offered 
significant benefits over placebo for the 
primary outcome, which was a com-
posite of five clinical measures: ambu-
lation index, standard neurological status, 
change from baseline in EDSS, number 
of relapses treated with corticosteroids, 
and time to first treated relapse.43 
Mitoxantrone provides short-term 
benefits by reducing relapse rate, devel-
opment of new cerebral lesions on MRI, 
and number of patients who experience 
deterioration of neurological function.43-45 
However, these studies were in a relatively 
small number of patients, and benefits on 
disability were not established. 
Serious potential side effects of 
mitoxantrone include dose-related im-
pairment of left ventricular ejection 
fraction and irreversible congestive heart 
failure when the cumulative lifetime dose 
exceeds 140 mg/m2 (use of mitoxantrone 
is limited to a maximum of 3 years at 
current dosage), birth defects when given 
during pregnancy or time of conception 
to both male and female partners, ste-
rility that may be permanent, and rarely 
leukaemia. 
Mitoxantrone is recommended for 
use as induction therapy in very active 
RRMS or as rescue treatment if patients 
do not respond to β-IFN or GA. It is 
licensed in the US for use in aggressive 
RRMS patients and SPMS patients with 
high relapse frequency, and recom-
mended for patients with unsatisfactory 
response to high-dose β-IFN or those 
with rapidly progressive disease.46 Most 
recently, serious side effects of mitox-
antrone, including congestive heart failure 
and therapy-related acute leukaemia, are 
reported to be more frequent than pre-
viously believed.47 With the availability 
of natalizumab, mitoxantrone use is be-
coming uncommon and less preferred.
Conclusion
DMDs should be considered for RRMS 
patients with active disease, but the 
timing of therapy initiation and the choice 
of DMDs should be individualized in view 
of differences in disease severity, relapse 
frequency, lifestyles, personal preference 
and funding support for these expensive 
therapies.
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Introduction
Physicians often come across patients who complain of frequent headaches. Most have episodic pain, but sometimes 
the headaches are present on a daily 
basis. Chronic daily headache (CDH) is a 
common problem, affecting around 5% 
of the general population; children as 
well as adults may be affected. It is not 
a single entity but a heterogeneous group 
of disorders, occurring by definition 15 
days per month for over 3 months.1,2
Primary headaches refer to dis-
orders that have no clear structural cause 
and are described as “benign”, but the 
associated disability can be substantial 
– depression, anxiety, impaired occupa-
tional and physical status. Primary CDH is 
categorized according to the duration of 
each episode – whether they last longer 
or shorter than 4 hours. (Table 1) Some 
headaches last for only a few seconds or 
minutes, the most well known of which 
is trigeminal neuralgia. Others include 
cluster headache, hypnic headache, par-
oxysmal hemicrania, primary stabbing 
headache, and short-lasting unilateral 
neuralgiform headache with conjunctival 
injection and tearing syndrome (SUNCT). 
The focus of this article is the first 
category in which episodes last for more 
than 4 hours. In this group, there are four 
forms of headache disorders: chronic mi-
graine (previously called transformed mi-
graine), chronic tension-type headache, 
new daily-persistent headache and hemi-
crania continua.
Headaches are secondary if at-
tributed to an underlying cause such as 
tumours, infection or inflammation.
Diagnosis
The first step in evaluation is to look for 
potentially serious pathology. This would 
be suspected in particular if certain 
red-flag features are present. (Table 2) 
Many individuals with chronic 
headache are concerned about a brain 
tumour or stroke.  In practice, patients 
with a stable pattern of headache for 1 
year usually do not have significant intrac-
ranial lesions. If the cranial magnetic res-
onance imaging (MRI) is normal, patients 
may feel relieved but frustrated because 
from their point of view, the pain remains 
“unexplained”. In few other neurological 
complaints are detailed history and exam-
ination as vital because there are no dis-
criminatory laboratory or radiological tests. 
Once secondary headaches have been 
excluded, the criteria for primary CDH are 
clinical and descriptive. The International 
Headache Society has published a useful 
but exhaustive classification of headache 
disorders, which is over 200 pages long 
plus references, on its website.3 
Chronic Migraine
Often, chronic migraine is preceded by 
a history of episodic migraine, which 
has increased in frequency over months 
and years until the patient suffers from 
daily migraneous or nonmigraneous 
headaches. The characteristic symptoms 
such as auras, photophobia, phonophobia 
and nausea may decrease during this 
transformation period. Risk factors for 
migraine transformation include female 
gender, obesity, frequent headaches at 
baseline and stressful life events.
Chronic Tension-type 
Headache
Most patients have bilateral nonthrobbing 
headache without migraine features 
such as aura, photophobia or nausea. 
This usually evolves from episodic 
tension headache and has a pressing 
or “tightening” quality. The attacks 
are not aggravated by walking or head 
movements.
New Daily Persistent Headache 
New daily persistent headache (NDPH) 
is a recently recognized form of primary 
CDH first described in 1984. It occurs in a 
person with no past history of headache 
although this is not an absolute factor. 
Typically, most patients can recall the 
exact day on which the pain started, and 
have experienced daily headache since 
that time. The diagnostic criteria for NDPH 
stipulate that pain must be present daily 
Table	1.	Differential	diagnosis	of	primary	
chronic	daily	headache
Headache	duration	>4	hours
Chronic migraine•	
Chronic tension-type headache•	
New daily persistent headache •	
Hemicrania continua•	
Headache	duration	<4	hours
With autonomic features
Cluster headache•	
Paroxysmal hemicrania•	
Short-lasting unilateral neuralgiform headache •	
with conjunctival injection and tearing syndrome 
(SUNCT) 
Without autonomic features
Trigeminal neuralgia•	
Idiopathic stabbing headache•	
Table	2.	Features	suggesting	a	secondary	
cause	of	headache
Systemic illness•	
New physical sign •	
Sudden onset •	
Onset age >40 years   •	
Progressive worsening of headache•	
Worst ever headache  •	
Headache worsening with cough•	
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Table	3.	Hemicrania	continua
A.		Headache	for	more	than	3	months	fulfilling	
three	other	criteria	from	B	to	D	below.
B.	All	of	the	following	characteristics:	
	 •	 	Unilateral	pain	without	side-shift	
	 •	 	Daily	and	continuous,	without	pain-free	periods	
	 •	 	Moderate	intensity,	but	with	exacerbations	of	
severe pain 
c.		At	least	one	of	the	following	autonomic	
features	that	occurs	during	exacerbations	
and	is	ipsilateral	to	the	side	of	pain:	
	 •	 	Conjunctival	injection	and/or	lacrimation
	 •	 	Nasal	congestion	and/or	rhinorrhoea	
	 •	 	Ptosis	and/or	miosis
D.		complete	response	to	therapeutic	doses	of	
indomethacin	
E.	Not	attributed	to	another	disorder
for more than 2 months with a duration of 
longer than 4 hours a day. The headaches 
are usually bilateral in location, and are 
described as throbbing or pressing in 
quality, with associated symptoms such 
as nausea, light sensitivity, sound sensi-
tivity, or light-headedness in more than 
half of the sufferers.
Hemicrania Continua
This is an uncommon condition and is a 
strictly unilateral headache disorder. The 
definition as adopted by the most recent 
2nd edition of the International Classifi-
cation of Headache Disorders is in Table 
3.2 It is important to recogize this form of 
CDH as it can be confused with cluster 
headache, and treatment for it can be 
quite effective.
Medication overuse Headache
All the headache disorders described 
above can be intensified by the overuse 
of prescription or over-the-counter anal-
gesics. In fact, the majority of patients 
who are referred to headache clinics 
exhibit analgesic overuse. The problem 
begins with individuals taking one or 
more drugs to treat headaches over an 
extended period; this paradoxically leads 
to more frequent pain and shortening 
periods between headache recurrence 
and drug consumption. Patients who 
consume simple analgesics such as 
paracetamol or non-steroidal anti-inflam-
matory drugs (NSAIDs) for ≥15 days per 
month are at risk of medication overuse 
headache. The threshold is reduced to 
≥10 days for drugs such as ergotamine, 
triptans and combination drugs.
Treatment
Treatment of CDH is challenging as 
usually there is no instant solution and 
sufferers may have consulted many 
other doctors and healthcare profes-
sionals. The objectives of treatment 
are to reduce the frequency, severity 
and duration of attacks, to reduce dis-
ability, and to improve daily function. A 
headache diary is advisable to document 
the frequency of attacks and analgesic 
consumption. First-line therapy is with 
advice on behavioural adjustments such 
as regular exercise, good sleep hygiene, 
trigger avoidance, stress reduction and a 
migraine diet. Some patients may obtain 
relief from psychotherapy or cognitive 
behaviour therapy, and there is anecdotal 
success with yoga and meditation. 
Medication overuse, if present, should 
be managed by stopping the offending 
drugs and using transition therapy with 
other analgesics such as NSAIDs or a 
short course of steroids.4 Sometimes 
inpatient detoxification regimens can be 
tried, in which the abused drug should 
be stopped and preventive drugs started 
along with anxiolytics, antiemetics and 
rescue therapy.
The mainstay of treatment of 
CDH is prophylactic drug therapy; most 
studies have concentrated on tricyclic an-
tidepressants (amitriptyline, nortriptyline), 
anticonvulsants (valproate, topiramate, 
gabapentin, pregabalin) and beta-blockers 
(propranolol, atenolol, metoprolol).5 Se-
lective serotonin reuptake inhibitors 
(fluoxetine) are useful in those with asso-
ciated psychiatric comorbidity. Botulinum 
toxin is expensive but can lead to marked 
improvement.  
Patients who do not respond to 
first-line treatment may need multiple 
prophylactic drugs to control headache 
attacks. Those with refractory headaches 
may be referred for specialist assessment 
for review of the diagnosis (to look for 
unusual causes such as idiopathic in-
tracranial hypertension and define the 
type of headache), and for management 
of chronic pain and medication overuse. 
Multidisciplinary care is required for pa-
tients with psychiatric morbidity and 
chemical dependency. 
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